Validity of the EQ–5D–5L and reference norms for the Spanish population

Hernández, Gimena; Garín, Olatz; Pardo, Yolanda; Vilagut, Gemma; Pont, Àngels; Suárez, Mónica; Neira, Montse; Rajmil, Luís; Gorostiza, Iñigo; Ramallo-Fariña, Yolanda; Cabases, Juan M.; Alonso, Jordi; Ferrer, Montse

doi:10.1007/s11136-018-1877-5

Cited by 117 publications

(98 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other endpoints of the present trial were the variations in the quality of life score (through the EQ-5D-5L questionnaire) and body mass index (BMI) (42). The previously validated Spanish version of the EQ-5D-5L questionnaire was used in the present study, which evaluates 5 general domains, each one with a score ranging from 0-4 (with a lower score indicating better quality of life) (43). Complete blood count (red and white blood cells), hemoglobin, hematocrit, platelets, kidney (serum creatinine, blood urea nitrogen-BUN-, uric acid) and liver function (albumin, bilirubin, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase and lactate dehydrogenase) serum test were monitored in all patients.…”

Section: Methodsmentioning

confidence: 99%

Decreased biochemical progression in patients with castration‑resistant prostate cancer using a novel mefenamic acid anti‑inflammatory therapy: A randomized controlled trial

et al. 2020

View full text Add to dashboard Cite

Prostate cancer (PCa) is the second most common non-dermatological cancer in men and is a growing public health problem. Castration-resistant disease (CRD) is the most advanced stage of the disease and is difficult to control. Patients with CRD may no longer accept conventional therapies as they are not in appropriate clinical conditions or they refuse to receive it. Given that inflammation is an essential component of CRD origin and progression, anti-inflammatory agents could be a therapeutic option with fenamates as one of the proposed choices. A prospective, randomized, double-blinded, 2-arm, parallel group, phase II-III clinical trial was performed involving 20 patients with CRD-PCa (with a prostate specific antigen level <100 ng/ml) that were undergoing androgen deprivation therapy (ADT) and did not accept any established treatment for that disease stage. In addition to ADT, 10 patients received placebo and 10 received mefenamic acid (500 mg orally every 12 h) for 6 months. The primary endpoint was the change in serum prostate-specific antigen (PSA) at 6 months. The PSA levels decreased significantly with mefenamic acid (an average 42% decrease), whereas there was an average 55% increase in the placebo group (P=0.024). In the patients treated with the placebo, 70% had biochemical disease progression (an increase of ≥25% in PSA levels), which did not occur in any of the patients treated with mefenamic acid (relative risk= 0.12; 95% confidence interval, 0.01-0.85; P= 0.033). There was a significant increase in quality of life (EQ-5D-5L score) and body mass index (BMI) with the experimental treatment. In conclusion, mefenamic acid administration decreased biochemical progression in patients with castration resistant PCa, improved their quality of life and increased their BMI. Future studies are required in order to strengthen the findings of the present clinical trial. Trial registration, Cuban Public Registry of Clinical Trials Database RPCEC00000248,

show abstract

Section: Methodsmentioning

confidence: 99%

Decreased biochemical progression in patients with castration‑resistant prostate cancer using a novel mefenamic acid anti‑inflammatory therapy: A randomized controlled trial

et al. 2020

View full text Add to dashboard Cite

show abstract

“…HRQoL was assessed with the paper-based Spanish version of the EQ-5D instrument [33], which has been validated in the Spanish population [34]. We used the three-level version (EQ-5D-3L) for patients aged between 12 and 18 years, the EQ-5D-3L proxy was completed by parents or caregivers of patients under 12 years, and the five-level version (EQ-5D-5L) was given to adults and caregivers.…”

Section: Methodsmentioning

confidence: 99%

Health-related quality of life in children and adults with X-linked hypophoshatemia

Yanes

Díaz-Curiel

Peris

et al. 2019

Preprint

View full text Add to dashboard Cite

Background X-linked hypophosphatemia (XLH) is an inherited type of severe rickets leading to deformities and can sometimes become a debilitating condition. Its impact on health-related quality of life (HRQoL) has not been extensively studied. Results Using standardized questionnaires in 21 children and 29 adults with confirmed XLH, we observed significant impaired HRQoL. Children had moderate problems in walking about (61.9%), washing or dressing themselves (9.52%), and performing their usual activities (33.33%). They also felt moderate pain or discomfort (61.9%) and were moderately anxious or depressed (23.81%). The mean EQ-5D-3L/EQ-5D-3L proxy index was 0.79 ± 0.15 and the mean VAS score was 68.33 ± 16.61. Adults had lower HRQoL, particularly with problems in walking (93%, with 3.45% unable to walk independently) and pain (86%, with 3.45% experiencing extreme pain). They also reported problems when carrying out their usual activities (80%) and washing or dressing themselves (>50%), and 65% of adult patients reported symptoms of anxiety and/or depression. The differences compared with the general Spanish population were significant, especially in the mobility and pain/discomfort dimensions of the EQ-5D-5L instrument. Caregivers and parents showed mild reduction in HRQoL, with a mean EQ-5D-5L index value (0.82 ± 0.16) and a mean VAS score (75.48 ± 17.24) smaller than that found in the general Spanish population. Conclusions X-linked hypophosphatemia reduced health-related quality of life despite treatment. These results evidenced limitations of conventional treatment in preventing disease complications, which in turn impaired quality of life in pediatric and adult patients.

show abstract

“…In addition, there is no a value set for EQ-5D-Y and then, it interferes with the calculation of QALYs [20]. This index was calculated by using the Spanish value set [25][26][27][28].…”

Section: Outcome Measuresmentioning

confidence: 99%

Cost-effectiveness and cost-utility analysis of a web-based computer-tailored intervention for prevention of binge drinking among Spanish adolescents

Vargas-Martínez

Lima‐Serrano

Trapero‐Bertran

2020

Preprint

View full text Add to dashboard Cite

BackgroundWorldwide, binge drinking (BD) today follows being a public health concern among adolescents. This study sought to assess the cost-effectiveness and cost-utility of a web-based computer-tailored intervention to prevent BD in adolescence.MethodsThe sample was drawn from a study evaluating the Alerta Alcohol programme. The population consisted of adolescents aged 15–19. Decision tree analysis was used to estimate costs and health outcomes, as measured by number of BD occasions and quality-adjusted life years (QALYs). Incremental Cost-Effectiveness and Cost-Utility Ratios were also calculated from National Health Service (NHS) and societal perspective and for a time horizon of four months. Multivariate deterministic sensitivity analysis of best/worst scenarios by subgroups was used to account for uncertainty.ResultsThe intervention was dominant from the societal perspective resulting in savings of €7,986.37 by one BD occasion averted per month. With regard to Incremental Cost-Utility Ratios, the intervention resulted in an incremental cost of €71.05 per QALY gained from NHS perspective and this was dominant, from societal perspective, resulting in savings of €34,126.64 per QALY gained in comparison with the control group. Subgroup analyses showed that the intervention resulted dominant for girls from both perspectives, and for those who were older (17 years or more) from NHS perspective.ConclusionComputer-tailored feedback is a cost-effective way to reduce BD and to increase QALYs among adolescents. However, long-term follow-up would probably be needed to capture major changes both in reduction of BD and in increasing of health-related quality of life.Trial registration(ClinicalTrials.gov): NCT03288896. Registration date: September 20, 2017. “Retrospectively registered”.

show abstract

Validity of the EQ–5D–5L and reference norms for the Spanish population

Abstract: The EQ-5D-5L is a valid instrument to measure perceived health in the Spanish-speaking population. The representative population-based norms provided here will help improve the interpretation of results obtained with the new EQ-5D-5L.

Cited by 117 publications

References 65 publications

Decreased biochemical progression in patients with castration‑resistant prostate cancer using a novel mefenamic acid anti‑inflammatory therapy: A randomized controlled trial

Decreased biochemical progression in patients with castration‑resistant prostate cancer using a novel mefenamic acid anti‑inflammatory therapy: A randomized controlled trial

Health-related quality of life in children and adults with X-linked hypophoshatemia

Cost-effectiveness and cost-utility analysis of a web-based computer-tailored intervention for prevention of binge drinking among Spanish adolescents

Contact Info

Product

Resources

About